EDAP TMS To Participate in Major International Congresses in Japan and Germany

EDAP TMS To Participate in Major International Congresses in
Japan and Germany 


VAULX-EN-VELIN, France, Sept. 16  /PRNewswire-FirstCall/ -- EDAP TMS S.A.
(NASDAQ:EDAP), a global leader in the development, marketing and distribution
of a portfolio of minimally-invasive medical devices for the treatment of
urological diseases, today announced its participation in two major upcoming
international congresses.

On September 18-20, 2004, EDAP will be present at the 4th International
Symposium on Therapeutic Ultrasound (ISTU) to be held in Kyoto, Japan. This
event gathers the international medical and scientific community investigating
in the development and the use of HIFU technology to treat a wide spectrum of
pathologies. This platform will be an opportunity for EDAP to present its
successful long term HIFU clinical results obtained with Ablatherm(R), based on
the treatment of more than 5,000 patients suffering from localized prostate
cancer. It will also allow EDAP to share its HIFU experience with other
investigators and discuss HIFU therapeutic breakthrough opportunities and
investments. EDAP's research partner INSERM, which has been actively working on
HIFU technology for years, will also be presenting its promising development
programs on therapeutic ultrasound.

On September 22-25, 2004, EDAP will be participating in the 56th Congress of
the German Society for Urology (D.G.U.: Deutsche Gesellschaft für Urologie)
taking place in Wiesbaden, Germany. Dr. Blana and Dr. Walter, from the Urology
Department of the Regensburg's University Hospital, will be presenting their
successful clinical results at five years using HIFU technology with Ablatherm.
During the congress, specific "Meet the Expert" meetings will be held daily on
our booth (#E24) for Urologists to discuss with clinicians about their HIFU
experience using Ablatherm on a daily practice. Germany is the 3rd biggest
world market for medical equipment and 22,000 new patients are being diagnosed
with prostate cancer every year. Approximately 2,000 HIFU treatments with the
Ablatherm have already been performed in Germany until today.

Hugues de Bantel, Chief Executive Officer of EDAP TMS, commented: "We are
particularly confident in the future growth of our Ablatherm business. The
successful introduction of mobile Ablatherm in Germany, with seven new hospital
users within the last ten months, confirms that Ablatherm is rapidly being
accepted as one of the most effective treatment alternative for localized
prostate cancer. Our participation in the ISTU Symposium, in Kyoto, together
with our long term research partner, further illustrates that we are determined
to expand HIFU technology to other pathologies and to position the Company to
meet this next challenge".

EDAP TMS S.A. is the global leader in the development, production, marketing
and distribution of a portfolio of minimally invasive medical devices primarily
for the treatment of urological diseases. The Company currently develops and
markets devices for the minimally invasive treatment of localized prostate
cancer, using High Intensity Focused Ultrasound (HIFU), through its EDAP SA
subsidiary; it is also developing this technology for the treatment of certain
other types of tumors. EDAP TMS S.A. also produces and commercializes medical
equipment for treatment of urinary tract stones using Extra-corporeal Shockwave
Lithotripsy (ESWL), via its TMS SA subsidiary. In addition, the Company markets
in Japan and Italy devices for the non-surgical treatment of benign Prostate
Hyperplasia (BPH) using Microwave Thermotherapy (TUMT). For more information,
contact the Investor Relations Department by phone at [phone]. For
additional information on the Company, please see the Company's web site at:
http://www.edap-tms.com/.

This press release contains, in addition to historical information,
forward-looking statements that involve risks and uncertainties. These include
statements regarding the Company's growth and expansion plans. Such statements
are based on management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ materially
from those described in the forward-looking statements. Factors that may cause
such a difference include, but are not limited to, those described in the
Company's filings with the Securities and Exchange Commission.

  CONTACT:      Hugues de Bantel - Philippe Chauveau
                  Blandine Confort
                  [phone]


DATASOURCE: EDAP TMS S.A.



CONTACT:  Hugues de Bantel, Philippe Chauveau or Blandine Confort, all

for EDAP TMS S.A., [phone]



Web site:  http://www.edap-tms.com/ 

Copyright